Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2017–2021

GlycoImaging · Imaging and detection of tumor-associated glycan structures on tumor cells

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-04-01 → 2021-09-30
Финансиране от ЕС
2 138 720 €
Участници
6
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Специални полимерни сензори разпознават захарни структури (гликани) върху раковите клетки, за да ги визуализират чрез наночастици и холография. Това помага за откриването на туморите в ранен етап, когато болестта е по-лесно лечима.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Imaging and detection of tumor-associated glycan structures on tumor cells

A major challenge in the war against cancer is to find ways to diagnose and treat the disease at an early stage. Cancer occurs through a multistage process where cells are transformed to malignant tumors. Of essence is to discover the tumor at an early stage where the cancer is still curable. This calls for sensitive and effective diagnostic tools that can sense the cellular state early in the process. In GlycoImaging we have addressed this need while exploiting novel molecularly imprinted polymers (MIPs) targeting glycans such as sialic acid, Tn and STn. These “plastic anti-bodies” were developed and used for visualization as cellular cancer biomarkers mainly in vitro using tumor cells cultured as monolayers and tumor cells cultured as 3D spheroids. 6 research groups, spread across 4 universities and institutes, and 1 industrial partner in 4 different countries have come together to train a new generation of chemists/biologists through the GlycoImaging PhD training network. Thereby we have created a highly interdisciplinary research-training network with ambitious scientific goals and an attractive training program. GlycoImaging aimed to develop and implement glycan specific probes in clinically relevant cancer diagnostics technologies. To conclude, we have developed glycan-specific nano-probes in different core-shell formats as well as carbon nanodots (CNDs)—against sialic acid, Tn or STn, respectively, alongside digital holography for real-time visualization of cancer biomarkers and use in life science and education. Moreover, we have developed and analyzed novel fluorophores for detection of MIP binding, including guanidinium benzoxadiazole fluorescent probes. The MIPs have been modified for immune cell analyses by addition of PEG structures. By using the genetically engineered HEK293 CRISPR/Cas9 isogenic cell lines, cell libraries were generated of Tn and STn O-glycoforms as well as different mucins. Thereafter, secreted mucin constructs were used to identify and validate the glyco-structures in the library by mass spectrometry. Mucins such as MUC1, MUC2 and MUC7 have been analysed.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The overall objective of Glyco Imaging is to develop novel assays for detection of glycans as biomarkers associated with aggressive and metastatic cancer forms. The assays will be developed for biomarker detection in blood, urine, cells and tissue. Molecularly Imprinted Polymers (MIPs), or plastic antibodies, have been developed for targeting the human glycan sialic acid (SA), or Neu5Ac. The efficiency of the Neu5Ac specific SAMIPs targeted to the biomarker SA in different solvents (methanol, water, phosphate buffer) will be exploited. The non-human Neu5Gc, which is incorporated into human glycoconjugates through dietary sources such as red meat, and shown to be involved in malignant cell transformation in humans, will also be investigated by using highly specific Neu5Gc-SAMIPs. The imaging and detection techniques used will be based on fluorescence, 3D-viewing of cancer cells by digital holographic microscopy and magnetic separation columns.The results in this research consortium will lead to major technological advances having impact on 1) health care, since it will develop more accurate and reliable diagnostics of aggressive and metastatic cancers, 2) drug discovery allowing a faster and cheaper biomarker targeting and detection; and 3) biochemistry research laboratories in resulting in improved understanding of glycan expression in cancer, with emphasis on aggressive metastatic cancer. The training of researchers will be performed by a consortium consisting of 6 partners with biomedical, imaging and particle synthesis skills (4 groups, one institution, one technology company). This forms the basis for a very competent interdisciplinary training program with high quality in both education and research. 8 early stage researchers (ESRs) working on specific tasks within 5 work packages will follow a rich training program providing a well-balanced spectrum of scientific, business and entrepreneurial skills.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз